Regeneron Pharmaceuticals (NasdaqGS:REGN) recently announced a strategic in-licensing agreement with Hansoh Pharmaceuticals, acquiring rights for a dual GLP-1/GIP receptor agonist, HS-20094.

SNY, BMY, REGN and others ramp up 2025 dealmaking as pharma/biotech giants chase innovation across key growth areas.

The acquisition of HS-20094 enhances Regeneron’s portfolio of obesity and metabolic programs, which aim to improve the quality of weight loss and address long-term health comorbidities.

Additionally, Regeneron has entered into a licensing agreement with Hansoh Pharmaceuticals for the obesity drug candidate HS-20094 ... $1.93 billion. This acquisition is expected to enhance ...

Additionally, Regeneron has entered into a licensing agreement with Hansoh Pharmaceuticals for the obesity drug candidate HS-20094, with an upfront payment of $80 million and potential future ...

Regeneron Pharmaceuticals, Inc. (REGN) on Monday said that it has entered into a strategic in-licensing agreement with ...

Major players including AbbVie, GSK, Sanofi, and Eli Lilly recently bolstered their R&D pipelines with a wave of acquisitions ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Regeneron Pharmaceuticals (REGN ... Hong Kong and Macau for a dual GLP-1/GIP receptor agonist, HS-20094, currently in Phase 3 testing.